Meeting
2015 ASCO Annual Meeting
Genotype-directed phase II study of irinotecan dosing in metastatic colorectal cancer (mCRC) patients receiving FOLFIRI + bevacizumab: The GENIC study.
Authors
Grant Richard Williams
UNC Chapel Hill, Chapel Hill, NC
Grant Richard Williams , Federico Innocenti , William Allen Wood , Jai Narendra Patel , Gary Bradley Sherrill , Bert H. O'Neil , Jeremiah C. Boles , Ethan M. Basch , Hanna Kelly Sanoff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT02138617
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS3621)
DOI
10.1200/jco.2015.33.15_suppl.tps3621
Abstract #
TPS3621
Poster Bd #
113b
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
A prospective, multicenter, randomized clinical trial of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting (PURE FIST).
First Author: Jaw-Yuan Wang
Poster
2012 Gastrointestinal Cancers Symposium
Phase II study alternating mFOLFOX 6 and FOLFIRI (FIREFOX) plus bevacizumab (bev) regimen in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0801).
First Author: Yutaka Ogata
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando
Poster
2022 ASCO Annual Meeting
Biweekly mXELIRI versus FOLFIRI in combination with bevacizumab as the first-line treatment for metastatic colorectal cancer (EXIST): A multicenter, randomized, open-label, phase 2 study.
First Author: Zhichao Jiang